LianBio Eyes ‘Strategic Review’ As It Hands Camzyos Asia Rights Back To MyoKardia Parent BMS

 
• By Alaric DeArment

BMS, which acquired MyoKardia in 2020 months after LianBio acquired rights in certain Asia-Pacific territories, said the deal would help expand its footprint in China.

BMS is spending $350m for rights in China and other Asia-Pacific territories for Camzyos • Source: Shutterstock

More from Deals

More from Business